The impact of prescription medication cost coverage on oral medication use for hypertension and type 2 diabetes mellitus
Auteurs: Razan Amoud, Kelly Grindrod, Martin Cooke, et Mhd Wasem Alsabbagh
Aperçu
Résumé (français)
Veuillez noter que les résumés n'apparaissent que dans la langue de la publication et peuvent ne pas avoir de traduction.
Résumé (anglais)
Background: No previous study, to the best of our knowledge, has examined both the time trend and impact of not having insurance or prescription medication cost coverage (PMCC) on the usage of type 2 diabetes and hypertension oral medications in Ontario and New Brunswick, Canada. Methods: We used data from the Canadian Community Health Survey (CCHS) from 2007 to 2014 to examine the time trend and impact of PMCC. A multivariable-adjusted logistic regression model was fitted. Results: The pseudo-cohort included 23,215 individuals representing a population of approximately 8.7 million people. Overall, 20.0% of respondents reported absence of PMCC. This proportion increased slightly from 19.6% (95% confidence interval [CI] 95% CI [17.5, 22.5]) to 20.7% (95% CI [16.9, 23.1]). Adjusted odds ratios (OR) showed that uninsured individuals were 23% less likely to use their medications (OR = 0.77, 95% CI [0.657, 0.911]). Conclusion: There was a slight decline in PMCC over time and this decline was associated with reduced use of medications for type 2 diabetes and hypertension.
Détails
Type | Article de journal |
---|---|
Auteur | Razan Amoud, Kelly Grindrod, Martin Cooke, et Mhd Wasem Alsabbagh |
Année de pulication | 2020 |
Titre | The impact of prescription medication cost coverage on oral medication use for hypertension and type 2 diabetes mellitus |
Volume | 16 |
Nom du Journal | Healthcare Policy |
Numéro | 2 |
Pages | 82-100 |
Langue de publication | Anglais |
- Razan Amoud
- Razan Amoud, Kelly Grindrod, Martin Cooke, et Mhd Wasem Alsabbagh
- The impact of prescription medication cost coverage on oral medication use for hypertension and type 2 diabetes mellitus
- Healthcare Policy
- 16
- 2020
- 2
- 82-100